PROCEPT BioRobotics Corporation

PRCT

Equity

ISIN null / Valor 113304787

NASDAQ (2025-12-26)

USD 32.41-1.43%

PROCEPT BioRobotics Corporation
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

PROCEPT BioRobotics Corporation is a pioneering medical technology company that specializes in the development and commercialization of robotic surgical systems. The company's flagship product, the AquaBeam Robotic System, represents a significant advancement in the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). This innovative system is distinguished by its use of Aquablation therapy, a unique, image-guided, and heat-free approach that offers a minimally invasive alternative to traditional surgical procedures. By leveraging robotic precision and real-time imaging, the AquaBeam Robotic System aims to improve patient outcomes, reduce recovery times, and provide a safer, more effective treatment option for millions of men worldwide suffering from BPH.

Summarized from source with an LLMView SourceSector: Technology

Revenue

Total revenue was $79.2 million for Q2 2025 (+48% year‑over‑year). U.S. revenue was $69.6 million (+46% YoY) driven by system sales and higher handpiece consumption; U.S. handpiece & consumables were $43.1 million (+58% YoY) and U.S. system & rental revenue was $22.1 million (+24% YoY). International revenue was $9.6 million (+69% YoY). The company sold 51 robotic systems in the U.S. in the quarter and the U.S. installed base was 595 systems as of June 30, 2025.

Profitability

Gross margin expanded to 65% in Q2 2025 (vs. 59% in Q2 2024 and 64% in Q1 2025), attributed to operational efficiencies, overhead absorption and higher U.S. system ASPs. Operating expenses rose to $73.9 million (from $58.3 million a year earlier). Net loss narrowed to $19.6 million (vs. $25.6 million in Q2 2024). Adjusted EBITDA loss improved to $8.0 million (vs. a $17.9 million loss prior year).

Liquidity & Balance Sheet

Cash, cash equivalents and restricted cash totaled $305.8 million as of June 30, 2025, and long‑term borrowings were $52.0 million.

2025 Guidance

The company raised full‑year 2025 revenue guidance to $325.5 million (approximately +45% vs 2024; prior guidance $323.0 million). It expects full‑year gross margin of ~64.5%, total operating expenses of ~$302.0 million (previously $300.0 million) and an Adjusted EBITDA loss of about ($35.0) million. Management noted a potential $1–$2 million gross margin headwind if global tariff rates remain at current levels.

Corporate / Commercial

PROCEPT reiterated focus on expanding Aquablation utilization, accelerating WATER IV trial enrollment and growing international commercial efforts. The company also announced Larry Wood will become CEO effective September 2, 2025.

Summarized from source with an LLMView Source

Key figures

-61.2%1Y

%3Y

%5Y

Performance

55.2%1Y

60.3%3Y

60.3%5Y

Volatility